HCPLive 5 Stories in Under 5: Week of 08/17
Update: 2025-08-22
Description
Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 Healthcare Headlines for August 17-23, 2025:
1. FDA Approves Donidalorsen to Prevent Hereditary Angioedema Attacks
The FDA approved donidalorsen (DAWNZERA) for preventing HAE attacks in patients 12 years and older, supported by phase 3 OASIS trial data.
2. FDA Grants Atumelnant Orphan Drug Designation for Congenital Adrenal Hyperplasia
Atumelnant received FDA Orphan Drug Designation after phase 2 results showed rapid, sustained reductions in key biomarkers for congenital adrenal hyperplasia.
3. Semaglutide Reduces Medical Costs, Healthcare Resource Utilization in Heart Failure
A real-world analysis found semaglutide 2.4 mg reduced all-cause medical costs by 28% and inpatient hospitalization costs by 55% in patients with obesity and heart failure.
4. RE104 Reduces Postpartum Depression Symptoms by Day 7 in Phase 2 RECONNECT
RE104 significantly reduced depressive symptoms by day 7 in patients with postpartum depression, meeting the phase 2 RECONNECT trial’s primary endpoint.
5. Dyslipidemia, Other Metabolic Syndrome Factors May Raise Parkinson’s Disease Risk
People with metabolic syndrome had about a 40% higher risk of developing Parkinson’s disease compared with those without the condition.
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 Healthcare Headlines for August 17-23, 2025:
1. FDA Approves Donidalorsen to Prevent Hereditary Angioedema Attacks
The FDA approved donidalorsen (DAWNZERA) for preventing HAE attacks in patients 12 years and older, supported by phase 3 OASIS trial data.
2. FDA Grants Atumelnant Orphan Drug Designation for Congenital Adrenal Hyperplasia
Atumelnant received FDA Orphan Drug Designation after phase 2 results showed rapid, sustained reductions in key biomarkers for congenital adrenal hyperplasia.
3. Semaglutide Reduces Medical Costs, Healthcare Resource Utilization in Heart Failure
A real-world analysis found semaglutide 2.4 mg reduced all-cause medical costs by 28% and inpatient hospitalization costs by 55% in patients with obesity and heart failure.
4. RE104 Reduces Postpartum Depression Symptoms by Day 7 in Phase 2 RECONNECT
RE104 significantly reduced depressive symptoms by day 7 in patients with postpartum depression, meeting the phase 2 RECONNECT trial’s primary endpoint.
5. Dyslipidemia, Other Metabolic Syndrome Factors May Raise Parkinson’s Disease Risk
People with metabolic syndrome had about a 40% higher risk of developing Parkinson’s disease compared with those without the condition.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
